BioPharmSignal logoBioPharmSignal

Biotech News

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Ocugen (OCGN)OcugenEarnings

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call.

Related news

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

SRPTSarepta Therapeutics2026-10-22 12:30 EST

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

LENZLenz Therapeutics Inc2026-10-22 12:00 EST

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

BLTEBelite Bio2026-08-13 01:45 EST

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SANASana Biotechnology2026-08-10 20:05 EST

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

View all latest news

Ocugen

Gene Therapies for Retinal Disease Ocugen develops one-time gene therapies for inherited and acquired causes of blindness. Its lead ophthalmology programs are designed to address broad patient populations rather than only individuals with a single disease-causing mutation. Modifier Gene Therapy Platform The platform delivers master...

Recent company news

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

OCGNOcugen2026-10-14 10:30 EST

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

OCGNOcugen2026-09-30 11:02 EST

Ocugen to Participate in Upcoming Scientific Conferences

OCGNOcugen2026-09-29 11:02 EST

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Stock data

Close
0.82 USD
Market cap
453.62M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States